About Us
Serimmune is an immune intelligence company focused on identifying and exploiting the universe of relationships between antibodies and antigens. Our proprietary technology provides a holistic view of the functional antibody repertoire to identify diverse immunogenic factors in disease and health. The company’s Serum Epitope Repertoire Analysis (SERA) technology platform combines a novel, random bacterial display peptide library with next generation sequencing, machine learning, and custom bioinformatics to reveal the many diverse antigens stimulating immunity. Serimmune’s human immunity map is a growing database that can be interrogated to fuel the development of multiplex diagnostics, vaccines and therapeutics.
Board of Directors
NOAH
NASSER
CEO, Serimmune
NICK
NACLERIO, PH.D.
Founding Partner, Illumina Ventures
BILL
WELCH, MBA
Partner, Illumina Ventures
KRISTIN
LOOMIS, MBA
President & Executive Director,
HHV-6 Foundation
PATRICK
DAUGHERTY, PH.D.
Founder & CSO, Serimmune
